Italy authorizes Dimetilfumarato Cipla capsules
Italy's medicines agency AIFA has authorized the sale of Dimetilfumarato Cipla, a dimethyl fumarate medicine made by Cipla Europe NV, in capsules of 120 mg and 240 mg. The decision is dated 17 February 2026 and covers several pack sizes. The packs are split into prescription-only and limited-prescription categories, with the larger packs restricted to neurologist or hospital prescription.
This summary was generated by AI; the official source prevails.
What does it mean?
Italy now allows Dimetilfumarato Cipla, a dimethyl fumarate medicine, to be sold in capsules of 120 mg and 240 mg. Dimethyl fumarate is a drug used for certain nerve conditions. The larger packs can only be dispensed on a neurologist's or hospital's prescription.
Who is affected?
Patients prescribed this medicine in Italy and the doctors who write those prescriptions.